[Reuters]–In a study by the University of Oxford in the UK on mixed vaccination with the new coronavirus vaccine, the immune response is enhanced when the first dose of AstraZeneca or Pfizer / Biontech is given and 9 weeks later, the modelna is given. The result was obtained.
Professor Matthew Snape of the university told Reuters that he had a much better immune response than two doses of the AstraZeneca vaccine.
The results of studies showing the effectiveness of mixed vaccination provide hope for low- and middle-income countries who may need to use different vaccines in the first and second doses due to unstable supply and other factors.
“The data from this study will be of particular interest and value to low- and middle-income countries that have not yet distributed the first two doses of vaccine,” Snape said.
“It has been shown that the same vaccine does not have to be used rigorously for the second dose, and that it is okay if multiple vaccines can accelerate the deployment of the vaccination program.” Told.
According to researchers at Oxford University, inoculation with AstraZeneca followed by Moderna or Novabax evoked a higher antibody-T cell response than two doses of Astra.
The effect of inoculating the Pfizer / Biontech product followed by the Moderna product was higher than that of the Pfizer / Biontec product inoculated twice.
Vaccination with Novavacs after Pfizer / Biontech elicited higher antibodies than the two doses of Astra, but the reaction between the antibody and T cells was higher than that of the two doses of Pfizer / Biontech. It was said that it was weak.
The study was published in the English medical journal The Lancet. No safety concerns have been raised.